Trexquant Investment LP Purchases 20,506 Shares of Illumina, Inc. (NASDAQ:ILMN)

Trexquant Investment LP boosted its position in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 16.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 142,977 shares of the life sciences company's stock after purchasing an additional 20,506 shares during the quarter. Trexquant Investment LP owned about 0.09% of Illumina worth $19,106,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently bought and sold shares of the company. Golden State Wealth Management LLC purchased a new stake in shares of Illumina in the fourth quarter worth $32,000. Versant Capital Management Inc raised its holdings in shares of Illumina by 153.7% in the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company's stock valued at $32,000 after acquiring an additional 146 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich purchased a new stake in shares of Illumina in the 4th quarter valued at about $45,000. Assetmark Inc. boosted its position in shares of Illumina by 954.8% during the 4th quarter. Assetmark Inc. now owns 327 shares of the life sciences company's stock valued at $44,000 after acquiring an additional 296 shares during the last quarter. Finally, Lee Danner & Bass Inc. purchased a new position in shares of Illumina during the fourth quarter worth about $48,000. 89.42% of the stock is owned by institutional investors.

Illumina Trading Down 3.0 %

ILMN traded down $2.26 during midday trading on Friday, reaching $74.16. 3,912,056 shares of the company's stock traded hands, compared to its average volume of 2,222,582. Illumina, Inc. has a 52 week low of $70.64 and a 52 week high of $156.66. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42. The firm has a fifty day moving average of $96.82 and a two-hundred day moving average of $125.06. The stock has a market capitalization of $11.75 billion, a price-to-earnings ratio of -9.66, a P/E/G ratio of 1.60 and a beta of 1.38.

Remove Ads

Illumina (NASDAQ:ILMN - Get Free Report) last posted its earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. On average, equities analysts anticipate that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ILMN has been the topic of a number of recent analyst reports. TD Cowen downgraded shares of Illumina from a "buy" rating to a "hold" rating and lowered their target price for the company from $177.00 to $140.00 in a research note on Friday, February 7th. Guggenheim dropped their price objective on shares of Illumina from $170.00 to $150.00 and set a "buy" rating for the company in a report on Friday, February 7th. Piper Sandler upped their target price on shares of Illumina from $185.00 to $190.00 and gave the stock an "overweight" rating in a research report on Monday, February 10th. Barclays restated an "underweight" rating on shares of Illumina in a research report on Tuesday, March 11th. Finally, HSBC lowered Illumina from a "buy" rating to a "hold" rating and set a $100.00 price objective on the stock. in a research report on Friday, February 28th. One investment analyst has rated the stock with a sell rating, ten have given a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $140.90.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.